AMPLIA THERAPEUTICS LIMITED

0.00%

13.0¢

Market Cap $66.69M

Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Latest Threads

Tag

Subject

ATX

Ann: Notification regarding unquoted securities - ATX

10/11/25

191

10/11/25

Last post

ASX News

191

ATX

Ann: FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL

10/11/25

7.8K

10/11/25

Last post vincenski

7.8K

ATX

ATX - General discussion

7 8 9

09/11/25

521

174K

09/11/25

Last post Catstar

521

174K

ATX

Ann: Amplia Commences Trading on U.S. OTCQB Venture Market

08/11/25

4.2K

08/11/25

Last post Garyb29336

4.2K

ATX

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

30/10/25

1.2K

30/10/25

Last post Eclectic_nish

1.2K

ATX

Ann: Amplia Therapeutics to Significantly Expand U.S. Presence

30/10/25

4.1K

30/10/25

Last post vrs37

4.1K

ATX

Ann: Amplia Receives R&D Tax Rebate Totalling $3.77 Million

28/10/25

263

28/10/25

Last post

ASX News

263

ATX

Ann: ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL

16/10/25

10K

16/10/25

Last post optimistic punter

10K

See All Discussions

Timeline

Notification regarding unquoted securities - ATX
10 Nov 16:42	Share

Amplia Commences Trading on U.S. OTCQB Venture Market
31 Oct 08:19	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Oct 09:03	Share

Amplia Receives R&D Tax Rebate Totalling $3.77 Million
28 Oct 09:13	Share

Amplia Therapeutics to Significantly Expand U.S. Presence
17 Oct 10:33	Share

ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL
09 Oct 08:24	Share

Notification of cessation of securities - ATX
08 Oct 09:48	Share

Patent Allowance for Key Narmafotinib Patent in US
30 Sep 08:36	Share

Change of Director's Interest Notice - Warwick Tong
08 Sep 12:22	Share

Change of Director's Interest Notice - Chris Burns
08 Sep 12:21	Share

Change of Director's Interest Notice - Robert Peach
08 Sep 12:20	Share

Change of Director's Interest Notice - Jane Bell
08 Sep 12:19	Share

Notification of cessation of securities - ATX
08 Sep 12:17	Share

FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL
04 Sep 08:18	Share

Notification of cessation of securities - ATX
02 Sep 17:48	Share

NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA
02 Sep 08:21	Share

Notification regarding unquoted securities - ATX
01 Sep 17:15	Share

Notification regarding unquoted securities - ATX
01 Sep 17:06	Share

Notice under Section 708A(5)(e) of the Corporations Act
01 Sep 09:49	Share

Application for quotation of securities - ATX
01 Sep 09:39	Share

Application for quotation of securities - ATX
01 Sep 09:35	Share

AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
29 Aug 08:24	Share

Application for quotation of securities - ATX
29 Aug 08:16	Share

Results of Annual General Meeting
27 Aug 11:58	Share

Managing Director's Presentation to AGM
27 Aug 10:08	Share

Amplia Share Purchase Plan Raises $2.65 Million
26 Aug 09:12	Share

Presentation - Targeting Pancreatic Cancer and Beyond
07 Aug 09:34	Share

Positive ACCENT Trial Topline Data Released
06 Aug 08:29	Share

Share Purchase Plan Prospectus
01 Aug 09:43	Share

Change of Registered Office and Principal Place of Business
01 Aug 08:20	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $66.69M

Open	High	Low	Value	Volume
13.0¢	13.0¢	12.5¢	$10.70K	82.85K

Buyers (Bids)

No.	Vol.	Price($)
2	77989	12.5¢

Sellers (Offers)

Price($)	Vol.	No.
13.0¢	90024	3

View Market Depth

No.	Vol.	Price($)
2	77989	0.125
3	141672	0.120
3	54060	0.115
5	74250	0.110
3	208556	0.105

Price($)	Vol.	No.
0.130	90008	2
0.135	55749	4
0.140	207026	2
0.145	315000	3
0.150	175487	5

Last trade - 16.10pm 10/11/2025 (20 minute delay)

ATX (ASX) Chart

AMPLIA THERAPEUTICS LIMITED

Latest Threads

The Next Big Market Move Is Closer Than You Think

Timeline

Featured News

Latest Videos

Amplia Therapeutics mints $2.4m R&D tax benefit

20 Oct 2023 10:46 (AEDT)

Latest Articles

Amplia tanks over -20% as ACCENT trial data underwhelms

The dangers of biotech were on display on Wednesday as Amplia Therapeutics (ASX:ATX), developing a cancer treatment called ACCENT, has failed to meet market expectations on the Wednesday session.

Amplia pops 40% on liquidity surge as chemo combo proves successful

Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes...

Amplia moves to next stage of cancer drug trial for narmafotinib

Amplia Therapeutics Ltd is set to move further through its Phase 2a trial for cancer drug narmafotinib, with four patients showing a response.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News